2020 - A Year Full Of Potentials, page-58

Good pick up @Sector and it is time to press this point.
Also good to see the company back out on the road with so much to come this year.
It would seem with MSBs recent shreprice strength that the world is coming to terms with the reality that stem cells will be commercial and it is the commercial production of our manufacturing process that differentiates us.
Good for us that MSBs market cap is again over $1.5b because it makes us look way to cheap.
With our phase II trials to be under way this quarter a huge stem cell focussed partner in Fujifilm as well as Sumitomo interested (and i doubt they have gone away) i doubt oyr stalled share price will be that way for long.
Time to be accumulating me thinks

DYOR or just read @pfeifer1982 and save yourself the time